Biblio

Jenkins LM, Singh P, Varadaraj A, Lee NY, Shah S, Flores HV, O'Connell K, Mythreye K.  2016.  Altering the Proteoglycan State of Transforming Growth Factor β Type III Receptor (TβRIII)/Betaglycan Modulates Canonical Wnt/β-Catenin Signaling.. J Biol Chem. 291(49):25716-25728.

Moutal A, Honnorat J, Massoma P, Désormeaux P, Bertrand C, Malleval C, Watrin C, Chounlamountri N, Mayeur M-E, Besançon R et al..  2015.  CRMP5 Controls Glioblastoma Cell Proliferation and Survival through Notch-Dependent Signaling.. Cancer Res. 75(17):3519-28.

Varadaraj A, Patel P, Serrao A, Bandyopadhay T, Lee NY, Jazaeri AA, Huang Z, Murphy SK, Mythreye K.  2015.  Epigenetic Regulation of GDF2 Suppresses Anoikis in Ovarian and Breast Epithelia.. Neoplasia. 17(11):826-38.

Samulitis BK, Pond KW, Pond E, Cress AE, Patel H, Wisner L, Patel C, Dorr RT, Landowski TH.  2015.  Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors.. Cancer Biol Ther. 16(1):43-51.

Zhang Y, Braithwaite A, Yuan Y, Streicher JM, Bilsky EJ.  2014.  Behavioral and cellular pharmacology characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) as a mu opioid receptor selective ligand.. Eur J Pharmacol. 736:124-30.

Lozano-Ondoua AN, Hanlon KE, Symons-Liguori AM, Largent-Milnes TM, Havelin JJ, Ferland HL, Chandramouli A, Owusu-Ankomah M, Nikolich-Zugich T, Bloom AP et al..  2013.  Disease modification of breast cancer-induced bone remodeling by cannabinoid 2 receptor agonists.. J Bone Miner Res. 28(1):92-107.

Roesly HB, Khan MR, Chen HDau Rw, Hill KA, Narendran N, Watts GS, Chen X, Dvorak K.  2012.  The decreased expression of Beclin-1 correlates with progression to esophageal adenocarcinoma: the role of deoxycholic acid.. Am J Physiol Gastrointest Liver Physiol. 302(8):G864-72.

Béguin C, Potuzak J, Xu W, Liu-Chen L-Y, Streicher JM, Groer CE, Bohn LM, Carlezon WA, Cohen BM.  2012.  Differential signaling properties at the kappa opioid receptor of 12-epi-salvinorin A and its analogues.. Bioorg Med Chem Lett. 22(2):1023-6.

Jandova J, Beyer TE, Meuillet EJ, Watts GS.  2012.  The matrix protein CCN1/CYR61 is required for α(V)β5-mediated cancer cell migration.. Cell Biochem Funct. 30(8):687-95.

Sukhtankar D, Okun A, Chandramouli A, Nelson MA, Vanderah TW, Cress AE, Porreca F, King T.  2011.  Inhibition of p38-MAPK signaling pathway attenuates breast cancer induced bone pain and disease progression in a murine model of cancer-induced bone pain.. Mol Pain. 7:81.

Novak P, Jensen T, Oshiro MM, Watts GS, Kim CJ, Futscher BW.  2008.  Agglomerative epigenetic aberrations are a common event in human breast cancer.. Cancer Res. 68(20):8616-25.

Yamamoto T, Nair P, Vagner J, Largent-Milnes T, Davis P, Ma S-W, Navratilova E, Moye S, Tumati S, Lai J et al..  2008.  A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid receptor agonists and neurokinin 1 receptor antagonists.. J Med Chem. 51(5):1369-76.

Goulet A-C, Watts G, Lord JL, Nelson MA.  2007.  Profiling of selenomethionine responsive genes in colon cancer by microarray analysis.. Cancer Biol Ther. 6(4):494-503.

Li H, Watts GS, Oshiro MM, Futscher BW, Domann FE.  2006.  AP-2alpha and AP-2gamma are transcriptional targets of p53 in human breast carcinoma cells.. Oncogene. 25(39):5405-15.

Novak P, Jensen T, Oshiro MM, Wozniak RJ, Nouzova M, Watts GS, Klimecki WT, Kim C, Futscher BW.  2006.  Epigenetic inactivation of the HOXA gene cluster in breast cancer.. Cancer Res. 66(22):10664-70.

Watts GS, Oshiro MM, Junk DJ, Wozniak RJ, Watterson S, Domann FE, Futscher BW.  2004.  The acetyltransferase p300/CBP-associated factor is a p53 target gene in breast tumor cells.. Neoplasia. 6(3):187-94.